Cross-Training Core for the Next Generation in Radiation Medicine
Official title: Cross-Training Core (ROBIN-NEST)
Funded at Dana-Farber Cancer Inst · NIH-11415798 · Data updated 2026-11-12
A program that joins experts across radiation medicine disciplines to build new cross-training, networking, and leadership development for future cancer researchers.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | September 19, 2023 |
| Project end | August 31, 2028 |
| Funding year | 2026 |
| Award (this year) | $97,094 |
| NIH project number | 5U54CA274516-04 |
| Project ID | NIH-11415798 on NIH RePORTER |
Who could benefit from this research
✓Could help
Not applicable to patient participation; focus is on training the next generation of professionals in radiation medicine.
✕Less likely to help
No direct patient participation in this grant, but future patients may benefit from a more interconnected workforce.
What this research studies
This grant supports a collaborative, cross-disciplinary education and training network in radiation medicine aimed at developing the next generation of leaders. It will create new didactic materials and a shared learning platform, promote knowledge-sharing across specialties, and provide professional development opportunities. Through partnerships with a broad learner and educator community, including outreach to local schools, it seeks to break down traditional training barriers and foster a more integrated workforce.
Why it matters
Potential benefit: If successful, patients could benefit from a more skilled and collaborative radiation medicine workforce delivering innovative care.
How similar studies have gone: Other cross-disciplinary training programs have shown the value of integrated education in accelerating translational impact.
Where this research is happening
-
Dana-Farber Cancer Inst
Boston, United States Active
Researchers
- Principal investigator: Berbeco, Ross I. — Dana-Farber Cancer Inst
- Study coordinator: Berbeco, Ross I.
Related research
Other NIH-funded projects on the same topics.
-
Helping young people with cancer understand their genetic risks
This study is creating a special program to help teenagers and young adults with hereditary cancer risks learn about their health and make smart choices, while also supporting their families along the way.
-
Core administrative hub for a multifaceted cancer center program
A large, international cancer research program at Dana-Farber aims to advance a curative strategy for multiple myeloma by coordinating translational research, clinical trials, and data analysis.
-
Automated, interactive lab tool to define radiation targets in cancer care
Aims to make it easier and safer to outline the area to treat in radiation therapy for cancers by using smart software and a patient-friendly interface.
-
Cancer Atlas Network data hub to share big cancer data
A national project helps researchers store, harmonize, and share large cancer data collections so doctors and scientists can learn from many patients.
-
Bridge-building cancer research partnership for education, outreach, and science
A joint effort between UMass Boston and Harvard Cancer Consortium to accelerate cancer research and education by connecting lower-resourced institutions with a leading cancer center.
-
NexTGen: Next-Generation T cell therapy for childhood cancers
A charity-friendly overview: researchers at Dana-Farber are developing advanced engineered T-cell therapies to treat pediatric solid cancers like brain tumors and sarcomas.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.